- Home
- FTW vs CLLS Comparison
FTW vs CLLS Comparison
Compare FTW & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$3.11
Company Overview
Basic Information| Metric | FTW | CLLS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.7M | 394.4M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FTW | CLLS |
|---|---|---|
| Price | $11.25 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 99.9K | 14.3K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.50 | $2.35 |
| 52 Week High | $17.20 | $5.48 |
Technical Indicators
Market Signals| Indicator | FTW | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 35.05 | 55.02 |
| Support Level | $11.12 | $3.00 |
| Resistance Level | $12.42 | $3.40 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 25.02 | 82.53 |
Price Performance
Historical Comparison FTW
CLLS
About FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
Presidio Production Co is a U.S.-based energy company focused on acquiring, operating and optimizing mature oil and gas assets with a disciplined, technology-driven model.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.